
-
Cellectis NasdaqGM:CLLS Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates. The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, an allogeneic engineered CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin's lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics, Inc.; and joint research and collaboration, and investment agreement with AstraZeneca Holdings B.V., as well as with AstraZeneca Ireland Limited. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Location: 8 rue de la Croix Jarry, Paris, 75013, France | Website: https://www.cellectis.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
72.69M
Cash
127.6M
Avg Qtr Burn
N/A
Short % of Float
0.56%
Insider Ownership
3.86%
Institutional Own.
21.49%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
UCART22 Details Acute lymphoblastic leukemia, Rare genetic disease, Cancer, B-cell acute lymphoblastic leukemia | Phase 1/2 Update | |
UCART20x22 Details Cancer, Non-Hodgkin lymphoma | Phase 1/2 Update | |
UCART123 Details Cancer, Relapsed/refractory acute myeloid leukemia | Phase 1 Data readout | |
ALLO-715 Details Cancer, Multiple myeloma | Failed Discontinued | |
ALLO-501 Details Non-Hodgkin lymphoma, Cancer | Failed Discontinued | |
UCART19 (anti-CD19) Details Cancer, Multiple myeloma, Acute lymphoblastic leukemia | Failed Discontinued | |
UCARTCS1 Details Cancer, Multiple myeloma, Menkes Disease | Failed Discontinued |